AAAAAA
Results: 1-25/29
Authors:
Levitt, NC
Eskens, FALM
O'Byrne, KJ
Propper, DJ
Denis, LJ
Owen, SJ
Choi, L
Foekens, JA
Wilner, S
Wood, JM
Nakajima, M
Talbot, DC
Steward, WP
Harris, AL
Verweij, J
Citation: Nc. Levitt et al., Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer, CLIN CANC R, 7(7), 2001, pp. 1912-1922
Authors:
van der Flier, S
van der Kwast, TH
Claassen, CJC
Timmermans, M
Brinkman, A
Henzen-Logmans, SC
Foekens, JA
Dorssers, LCJ
Citation: S. Van Der Flier et al., Immunohistochemical study of the BCAR1/p130Cas protein in non-malignant and malignant human breast tissue, INT J B MAR, 16(3), 2001, pp. 172-178
Authors:
Meijer-van Gelder, ME
Look, MP
Bolt-de Vries, J
Peters, HA
Klijn, JGM
Foekens, JA
Citation: Me. Meijer-van Gelder et al., Clinical relevance of biologic factors in male breast cancer, BREAST CANC, 68(3), 2001, pp. 249-260
Authors:
Dorssers, LCJ
van der Flier, S
Brinkman, A
van Agthoven, T
Veldscholte, J
Berns, EMJJ
Klijn, JGM
Beex, LVAM
Foekens, JA
Citation: Lcj. Dorssers et al., Tamoxifen resistance in breast cancer - Elucidating mechanisms, DRUGS, 61(12), 2001, pp. 1721-1733
Authors:
Foekens, JA
Romain, S
Look, MP
Martin, PM
Klijn, JGM
Citation: Ja. Foekens et al., Thymidine kinase and thymidylate synthase in advanced breast cancer: Response to tamoxifen and chemotherapy, CANCER RES, 61(4), 2001, pp. 1421-1425
Authors:
Foekens, JA
Peters, HA
Grebenchtchikov, N
Look, MP
Meijer-van Gelder, ME
Geurts-Moespot, A
van der Kwast, TH
Sweep, CGJ
Klijn, JGM
Citation: Ja. Foekens et al., High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer, CANCER RES, 61(14), 2001, pp. 5407-5414
Authors:
Schuyer, M
van der Burg, MEL
Henzen-Logmans, SC
Fieret, JH
Klijn, JGM
Look, MP
Foekens, JA
Stoter, G
Berns, EMJJ
Citation: M. Schuyer et al., Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2, BR J CANC, 85(9), 2001, pp. 1359-1367
Authors:
Berns, EMJJ
van Staveren, IL
Verhoog, L
van de Ouweland, AMW
Meijer-van Gelder, M
Meijers-Heijboer, H
Portengen, H
Foekens, JA
Dorssers, LCJ
Klijn, JGM
Citation: Emjj. Berns et al., Molecular profiles of BRCA1-mutated and matched sporadic breast tumours: relation with clinico-pathological features, BR J CANC, 85(4), 2001, pp. 538-545
Authors:
de Witte, JH
Foekens, JA
Brunner, N
Heuvel, JJTM
van Tienoven, TH
Look, MP
Klijn, JGM
Geurts-Moespot, A
Grebenchtchikov, N
Benraad, TJ
Sweep, CGJ
Citation: Jh. De Witte et al., Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours, BR J CANC, 85(1), 2001, pp. 85-92
Authors:
Fina, F
Romain, S
Ouafik, LH
Palmari, J
Ben Ayed, F
Benharkat, S
Bonnier, P
Spyratos, F
Foekens, JA
Rose, C
Citation: F. Fina et al., Frequency and genome load of Epstein-Barr virus in 509 breast cancers fromdifferent geographical areas, BR J CANC, 84(6), 2001, pp. 783-790
Authors:
van der Flier, S
Brinkman, A
Look, MP
Kok, EM
Meijer-van Gelder, ME
Klijn, JGM
Dorssers, LCJ
Foekens, JA
Citation: S. Van Der Flier et al., Bcar1/p130Cas protein and primary breast cancer: Prognosis and response totamoxifen treatment, J NAT CANC, 92(2), 2000, pp. 120-127
Authors:
Salden, M
Splinter, TAW
Peters, HA
Look, MP
Timmermans, M
van Meerbeeck, JPAM
Foekens, JA
Citation: M. Salden et al., The urokinase-type plasminogen activator system in resected non-small-celllung cancer, ANN ONCOL, 11(3), 2000, pp. 327-332
Value of estrogenic recruitment before chemotherapy: First randomized trial in primary breast cancer
Authors:
Bontenbal, M
van Putten, WLJ
Burghouts, JTM
Baggen, MGA
Ras, GJ
Stiegelis, WF
Beudeker, M
Janssen, JTP
Braun, JJ
van der Linden, GHM
van der Velden, PC
van Geel, AN
Helle, P
Leisink, M
Foekens, JA
Klijn, JGM
Citation: M. Bontenbal et al., Value of estrogenic recruitment before chemotherapy: First randomized trial in primary breast cancer, J CL ONCOL, 18(4), 2000, pp. 734-742
Authors:
Klijn, JGM
Setyono-Han, B
Foekens, JA
Citation: Jgm. Klijn et al., Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer, STEROIDS, 65(10-11), 2000, pp. 825-830
Authors:
Berns, EMJJ
Foekens, JA
Vossen, R
Look, MP
Devilee, P
Henzen-Logmans, SC
van Staveren, IL
van Putten, WLJ
Inganas, M
Meijer-van Gelder, ME
Cornelisse, C
Claassen, CJC
Portengen, H
Bakker, B
Klijn, JGM
Citation: Emjj. Berns et al., Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer, CANCER RES, 60(8), 2000, pp. 2155-2162
Authors:
Foekens, JA
Peters, HA
Look, MP
Portengen, H
Schmitt, M
Kramer, MD
Brunner, N
Janicke, F
Meijer-van Gelder, ME
Henzen-Logmans, SC
van Putten, WLJ
Klijn, JGM
Citation: Ja. Foekens et al., The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients, CANCER RES, 60(3), 2000, pp. 636-643
Authors:
Look, MP
Foekens, JA
Citation: Mp. Look et Ja. Foekens, Clinical relevance of the urokinase plasminogen activator system in breastcancer, APMIS, 107(1), 1999, pp. 150-159
Authors:
Meijer-van Gelder, ME
Look, MP
Bolt-de Vries, J
Peters, HA
Klijn, JGM
Foekens, JA
Citation: Me. Meijer-van Gelder et al., Breast-conserving therapy: Proteases as risk factors in relation to survival after local relapse, J CL ONCOL, 17(5), 1999, pp. 1449-1457
Authors:
Sieuwerts, AM
Klijn, JGM
Foekens, JA
Citation: Am. Sieuwerts et al., Insulin-like growth factor 1 (ICF-1) and urokinase-type plasminogen activator (uPA) are inversely related in human breast fibroblasts, MOL C ENDOC, 154(1-2), 1999, pp. 179-185
Authors:
Schuyer, M
Henzen-Logmans, SC
van der Burg, MEL
Fieret, JH
Derksen, C
Look, MP
Meijer-van Gelder, ME
Klijn, JGM
Foekens, JA
Berns, EMJJ
Citation: M. Schuyer et al., Genetic alterations in ovarian borderline tumours and ovarian carcinomas, EUR J OB GY, 82(2), 1999, pp. 147-150
Authors:
Sieuwerts, AM
Klijn, JGM
Henzen-Logmans, SC
Foekens, JA
Citation: Am. Sieuwerts et al., Cytokine-regulated urokinase-type-plasminogen-activator (uPA) production by human breast fibroblasts in vitro, BREAST CANC, 55(1), 1999, pp. 9-20
Authors:
Foekens, JA
Dall, P
Klijn, JGM
Skroch-Angel, P
Claassen, CJC
Look, MP
Ponta, H
Van Putten, WLJ
Herrlich, P
Henzen-Logmans, SC
Citation: Ja. Foekens et al., Prognostic value of CD44 variant expression in primary breast cancer, INT J CANC, 84(3), 1999, pp. 209-215
Authors:
Los, M
Zeamari, S
Foekens, JA
Gebbink, MFBG
Voest, EE
Citation: M. Los et al., Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene, CANCER RES, 59(17), 1999, pp. 4440-4445
Authors:
de Witte, JH
Sweep, CGJ
Klijn, JGM
Grebenschikov, N
Peters, HA
Look, MP
van Tienoven, TH
Heuvel, JJTM
Vries, JBD
Benraad, TJ
Foekens, JA
Citation: Jh. De Witte et al., Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer, BR J CANC, 80(1-2), 1999, pp. 286-294
Authors:
de Witte, JH
Sweep, CGJ
Klijn, JGM
Grebenschikov, N
Peters, HA
Look, MP
van Tienoven, TH
Heuvel, JJTM
van Putten, WLJ
Benraad, TJ
Foekens, JA
Citation: Jh. De Witte et al., Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients, BR J CANC, 79(7-8), 1999, pp. 1190-1198